The CDNR Platform – Progressing the Promise of Personalized Medicine

April 9, 2018 | Posted by Team in Innovation Highlight |

by Gursatya “Guru” Singh, Director of Scientific Content, Science Exchange

Most everyone knows that precision medicine promises to transform the healthcare landscape, delivering powerful and personalized treatments for previously intractable diseases. Even so, biotech innovators still face tremendous hurdles in realizing this promise — chief among them, finding access to sufficient numbers of annotated, characterized and consented patient samples.

Novaseek Research has developed a unique solution to this dilemma: the Clinical Data Network for Research platform — otherwise known as CDNR.

CDNR Novaseek Research Science Exchange

CDNR provides instant access to thousands of ethically-sourced patients’ specimens and associated real-world clinical data in pursuit of advancing the field of personalized medicine. Novaseek obtains biosamples and associated data through its extensive network of physicians, clinical labs, and hospitals. Within this network, Novaseek actively recruits patients to match targeted research needs. Novaseek also maintains a large searchable database of de-identified clinical information representing millions of patients.

Through the Novaseek platform, researchers can easily obtain the data they need throughout the product life cycle. For instance, researchers seeking the statistics necessary for in vitro diagnostics submissions can gain access to sufficient numbers of annotated, characterized and consented patient samples and related data. With CDNR, obtaining clinical data and biospecimens is seamlessly integrated into R&D.

Learn more about Novaseek Research on their Science Exchange storefront.

 

Science Exchange Announces Outsourced R&D Partnership with Alector

November 20, 2017 | Posted by Team in News |

Science Exchange-Alector PartnershipPALO ALTO, Calif.–Science Exchange, the world’s leading and most secure enterprise platform and aggregator for outsourced research and development (R&D), today announced a strategic partnership with Alector, a biotech company pioneering the discovery & development of immuno-neurology therapies for neurodegenerative disorders, to provide the company’s scientists access to a private R&D marketplace to accelerate their research.

“The Science Exchange platform solves the challenges of R&D outsourcing: we provide scientists with efficient access to a diverse network of qualified suppliers under a single relationship, and at the same time we provide sourcing departments with more information and control over their outsourcing spend,” said Elizabeth Iorns, Ph.D., co-founder and CEO of Science Exchange. “We are thrilled to be the provider of Alector’s R&D marketplace and help bring potential treatments for Alzheimer’s disease to patients more quickly and efficiently. Especially following the exciting news on Alector’s partnership with AbbVie to advance therapies for Alzheimer’s disease, it’s clear that Alector has extremely promising drug targets — we’re honored to help accelerate these important discoveries.”

The Science Exchange-powered R&D marketplace enables scientists to instantly order more than 6,000 unique scientific services from the 2,500 CROs, academic labs, and government facilities that are available under a single Science Exchange contract. The partnership also will provide Alector with a platform to effectively manage the company’s outsourced R&D investments, including the ability to track supplier utilization, trends, and performance, which also supports the need for compliance with internal policies and external regulations.

Alector is the latest R&D company to choose to partner with Science Exchange, and joins more than 30 enterprise organizations, including 10 of the top 20 pharma companies, that use Science Exchange to more efficiently manage outsourced R&D.

“Science Exchange offers a unique platform for connecting with a broad network of qualified scientific service providers,” said Arnon Rosenthal, Ph.D., co-founder and CEO of Alector. “It is our hope that working with Science Exchange will enable us to more quickly advance discovery and development of novel immuno-neurology therapies.”

Under the agreement, Science Exchange will support company-specific governance, approval workflows, and preferred vendors. To minimize the risk frequently associated with outsourcing to external service providers, the Science Exchange guarantee ensures complete protection of data, assets and performance of agreed-upon services, all backed by a best-in-class, SOC 2-compliant information technology security infrastructure. Science Exchange’s ISO 9001-certified quality assurance system and dedicated regulatory compliance team also support regulated work.

 

Visit www.scienceexchange.com/enterprise to request a demo of our award-winning private marketplaces for managing outsourced research and development!

QB3 Signs Partnership with Science Exchange

October 23, 2017 | Posted by Team in News |

Qb3 Partners With Science ExchangeBay Area Life Science Hub Enables its Startups to Stay Lean with Science Exchange’s R&D Platform

PALO ALTO, CA, October 23, 2017Science Exchange, a platform for outsourced research and development (R&D) services, today announced a partnership with QB3, the University of California hub for innovation and entrepreneurship for life sciences.

Through an exclusive Science Exchange-QB3 marketplace, QB3-affiliated companies will now have access to a customized and secure marketplace where they can instantly order R&D services from a network of more than 2,500 qualified scientific service providers. Science Exchange’s scientific concierge staff also will offer support to QB3’s start-up companies in identifying innovative providers and ordering complex R&D services.

“Science Exchange will help accelerate our companies by giving them access to providers that are experienced with entrepreneurial research and that have already been reviewed and qualified,” said Ioana Aanei, Ph.D., Entrepreneurship Program Manager at QB3. “Many of our startups don’t have the resources to purchase their own capital equipment or do the necessary specialized scientific research in-house.”

“Science Exchange is committed to helping life science companies bring innovative, potentially life-saving products to market,” said Elizabeth Iorns, Ph.D., Founder & CEO of Science Exchange. “While QB3’s companies focus on discovery, we can help eliminate the barriers, including the time and expertise needed to research and qualify contract research organizations (CROs) and scientific service providers. We also help save time and money in contract negotiation, all while ensuring the protection of intellectual property.”

QB3 joins more than 30 enterprise clients and entrepreneurial incubators that are efficiently managing their outsourced R&D with Science Exchange-powered marketplaces.

About QB3

QB3 is the University of California’s hub for innovation and entrepreneurship in the life sciences. The institute supports UC researchers and empowers Bay Area entrepreneurs to launch startup companies and partner with industry. QB3 helps bio-entrepreneurs create hundreds of high-value jobs and bring more than $750 million into the Bay Area each year. With campus divisions at Berkeley, San Francisco, and Santa Cruz, QB3 is also affiliated with the San Francisco incubator [email protected] — home to more than 45 companies — and the seed-stage venture capital firm Mission Bay Capital. Visit us at http://qb3.org/.

 

Science Exchange Raises $28M in Series C Funding

June 29, 2017 | Posted by Team in News |
Science Exchange Team

The Science Exchange Team

Funding led by Norwest Venture Partners with participation from Union Square Ventures, Maverick Capital and Collaborative Fund

Palo Alto, CA – June 29, 2017 As further evidence of its position as the world’s leading platform for outsourced research and development (R&D), Science Exchange today announced it has raised $28 million in Series C funding. Founded in response to the global growth in outsourced R&D services, the company has raised more than $58 million since its inception in 2011. Norwest Venture Partners led the latest round with participation from existing investors Union Square Ventures, Maverick Capital, and Collaborative Fund.

“In the last decade, outsourcing of R&D has become a core strategy for improving efficiency and providing access to innovation for top companies globally. Forty percent of R&D spend is now outsourced and this trend continues to grow,” explained Science Exchange CEO Elizabeth Iorns, Ph.D., a research scientist who co-founded the company. “At the same time, businesses are challenged to manage their outsourced R&D. They need to track progress and provider performance across what could be hundreds of service provider relationships, impacting the cost, quality and timeliness of research projects. The Science Exchange platform solves this by removing barriers in the outsourcing process – providing companies with instant access to a network of pre-qualified service providers, as well as contracting, project management and reporting tools.”

As part of the Series C, Casper de Clercq, General Partner at Norwest and veteran of the life sciences industry with more than 20 years of commercialization and operating experience, will join the company’s board.

“Science Exchange has developed an outsourcing platform that is enjoying tremendous momentum as many of the world’s largest pharma and biotech companies have signed up,” said Casper de Clercq, General Partner at Norwest. “They are well-positioned as the leader in a large and expanding market. We are excited to help Science Exchange become the world’s largest platform for outsourced R&D.”

“We’re thrilled to be partnering with such prestigious investors to help us grow our business at such a critical time in the evolution of R&D outsourcing,” commented Iorns. “This investor confidence confirms our business strategy and potential for continued growth.”

Through the Science Exchange platform, researchers have easy and secure access to more than 2,500 of the world’s premier outsourced R&D service providers — qualified contract research organizations (CROs), contract manufacturers (CMOs), academic labs, and government facilities. Thousands of scientists have used the platform to support their pursuit of breakthrough scientific discoveries, including those from 10 of the top 20 biopharma companies. In fact, the company has grown its enterprise-wide strategic sourcing agreements with leading pharmaceutical companies by more than 2,000 percent since 2015.

Science Exchange plans to use the funding to continue its expansion beyond biopharma into other industries where scientists are faced with R&D outsourcing challenges – including agricultural science, cosmetics, aerospace and industrial chemicals. The company will strategically hire across product, engineering, sales, marketing, and customer success.

About Science Exchange
Science Exchange is the world’s leading platform for outsourced research, providing an efficient procure-to-pay platform for ordering services from a network of more than 2,500 qualified scientific service providers, all with pre-established contracts in place that protect client intellectual property and confidentiality. The platform increases scientists’ access to innovation and improves productivity, freeing them up from the administrative tasks and delays associated with sourcing, establishing and managing service provider contracts. Additionally, the Science Exchange enterprise program enables organizations to consolidate research R&D outsourcing spend into a single strategic relationship, driving efficiency and cost savings. Since being founded in 2011, Science Exchange has raised more than $58 million from Norwest Venture Partners, Maverick Capital Ventures, Union Square Ventures, Collaborative Fund, Index Ventures, OATV, the YC Continuity Fund, and others. For more information, visit http://www.scienceexchange.com. Follow the company on Twitter @ScienceExchange.

About Norwest Venture Partners

Norwest Venture Partners is a leading Silicon-Valley based venture capital and growth equity investment firm managing more than $6 billion in capital. Since our inception, we have invested in more than 600 companies. The firm invests in early to late stage companies across a wide range of sectors with a focus on consumer, enterprise, and healthcare. We offer a deep network of connections, operating experience, and a wide range of impactful services to help CEOs and founders advance on their journey. Norwest has offices in Palo Alto and San Francisco, with subsidiaries in Mumbai and Bengaluru, India and Herzelia, Israel. For more information, please visit http://www.nvp.com. Follow Norwest on Twitter @NorwestVP.

# # #

Media Contacts

Kerry Metzdorf
Representing Science Exchange
[email protected]
978-463-2575

Ellie Javadi
Norwest Venture Partners
[email protected]
650-289-2227

 

Science Exchange Stories: Pat Corsino from Nuovo Biologics

April 29, 2014 | Posted by Tess Mayall in Scientist Profile |

1-p2

Our user Pat Corsino, a R&D Manager at Nuovo Biologics, is studying the mechanism of action behind their antiviral and oncology technologies. I spoke with him about life and efficiency at an early-stage biotech, check out his advice about being proactive at a small biotech!

Q: What does Nuovo Biologics do?

Pat: We’re a small biotech company. We’re working on novel antiviral and anti-cancer therapeutics.

Q: How often does Nuovo Biologics contract out experiments?

Pat: Quite a bit, we have several collaborators all over the country. They help us plan and perform experiments, because we have limited capabilities in house. Right now, we need to get experiments done quickly in order to get funding to expand our laboratory.

Many collaborators do experiments for us, but sometimes there are projects that we can’t do through our network. That’s where Science Exchange comes in handy, because there’s a wealth of different experiments on the site. Read the rest of this entry »

Science Exchange Stories: OncoSynergy, fighting brain cancer as the family business

January 21, 2014 | Posted by Tess Mayall in Scientist Profile |
Shawn Carbonell, MD, PhD and wife Anne-Marie Carbonell, MD, OncoSynergy’s new VP of Clinical Development

Shawn Carbonell, MD, PhD and wife Anne-Marie Carbonell, MD, OncoSynergy’s new VP of Clinical Development

This week I got to catch up with our user Shawn Carbonell and his biotech company OncoSynergy, who has made exciting progress in the 2 months since we last talked. They were honored with the Children’s Humanitarian Award from the Children’s Tumor Foundation at their annual Gala in New York City and have just announced they are the Social Media Sponsor of the 2014 Race for Hope for brain cancer research held in conjunction with Accelerate Brain Cancer Cure (ABC2) and the National Brain Tumor Society. However, perhaps most importantly, Shawn Carbonell’s wife, Anne-Marie Carbonell, has joined the OncoSynergy team as Vice President of Clinical Development.

To put it in his words, “When I found out she was single and was no longer in neurosurgery I made it my mission to both marry her and hire her. Last month both became reality.”

There are so many fascinating elements to Anne-Marie. Both Shawn and Anne-Marie successfully matched into neurosurgery residency only to find new career tracks; they’re now making the fight against brain cancer the family business. That’s only a small fraction of the incredible story, read the rest below! Read the rest of this entry »

Small Biotech Stories: Eos Neuroscience

November 26, 2013 | Posted by Brianne Villano in Innovation Highlight |

Eos Neuroscience is a company built on collaboration, featuring a unique team with expertise in transgenes, virology and gene expression, and retinal degeneration. Once they complete their preclinical stage, their intended userbase would be those with blindness attributed to photoreceptor degeneration, or age-related macular degeneration.

They are running into some problems in the process of preclinical research, however. Alan Horsager, Co-Founder and CSO, describes his experience, “As a whole, biotech needs to deeply reevaluate the process, all the way from discovery to market. It’s so arduous that so few impactful drugs make it to market. There are certain gene therapies making it through, but the path is not easy at all. We say ’20 years and $200 million.'”

In light of difficulties and the expense of developing technologies, companies like Alan’s are trying to find ways to do things more efficiently, and their team is so unique that it’s difficult to recreate that collaboration. So rather than trying to clone themselves, they’re on Science Exchange.

“Science Exchange provides the opportunity to bring experts together toward a common goal, a network of distributed team members.” says Alan. “You can’t have an organization that has all the people and equipment that you need. You need expertise in different areas and Science Exchange provides a central location where you can go to get the experts.”

If your business encompasses multiple research areas, it is often difficult to access all the equipment and researchers you need in house. Eos does a wide range of research including vector development, qPCR, and gene expression, but in varying degrees and not constantly. So having the ability to do all that in house when you’re not doing the research full-time doesn’t make much sense.

Alan elaborated, “You can hire a postdoc for $70K per year, and theoretically they do more than a PCR assay, but if they don’t do it right it takes extra time and there’s a lot of training involved. If you’re only doing a couple of different assays, it’s probably better to hire someone and do it internally. But if you’re doing a lot of different assays, it’s better to seek external experts because it’s a fraction of the cost.”

We have actually found that researchers can save up to 46% on various experiments like immunohistochemistry (IHC), cloning, and sequencing, so Alan is absolutely right. Any product that enables you to order services from scientific experts across the world at significant discounts is worth a second look.

About Eos Neuroscience:
Eos has designed and managed clinical programs in gene therapy and the eye and has been involved in all aspects of primary research including transgenes, virology and gene expression, and retinal degeneration. Their worldwide core of experts has expertise covering basic research through clinical/regulatory.

About the author

    Brianne is dedicated to customer support and development for Science Exchange. She     is a formally trained biologist with a M.S. in Biotechnology whose past experience at           Charles River Laboratories sparked a flame for building client relationships.

 

Science Exchange Stories: Shawn Carbonell, Brain Surgery Dropout

November 13, 2013 | Posted by Tess Mayall in Scientist Profile |
Shawn Carbonell at his small lab space in San Francisco. Photo from Jackson Solway's Startup Portrait.

Shawn Carbonell at his small lab space in San Francisco. Photo from Jackson Solway’s Startup Portrait.

Have you ever had a big idea that burned a hole in your brain? Plagued you day after day? Well, that’s exactly what happened to Shawn Carbonell, the CEO and Chief Scientific Officer of OncoSynergy.

Although he had spent the last 18 years prepping for a career as an academic neurosurgeon, he couldn’t stop thinking about an idea he had that could help fight cancer.  He had many options available to him, but he risked it all because he wanted to get a drug to the clinic in the quickest way possible.

I talked with Shawn a few weeks ago, I was impressed not only with the passion he has embodied to develop his cancer therapies, but also the speed at which he has done so (P.S. I’ve visited Shawn’s lab in San Francisco, and can say, hands-down, it is the most efficient lab I’ve ever visited). Read the rest of this entry »

Small Biotech Stories: American CryoStem

October 29, 2013 | Posted by Brianne Villano in New Innovations |

American_CryoStem_Logo_larg

Some companies skirt regulations, opting instead to go off the radar. American CryoStem‘s Anthony Dudzinski‘s first words to me on the phone during our discussion were, “We follow the rules.” They’ve accumulated the greatest depth of adipose tissue-based cellular technology research relative to creating their laboratory and processes at a clinical cGMP level, and they’ve done it by actively engaging FDA consultants in the process.

Anthony F. Dudzinski, COO at American CryStem

Anthony F. Dudzinski, COO at American CryoStem

They’re looking at adipose-derived stem cells – also known as mesenchymal cells. ‘Mesenchymal’ was the original name of cells that came from bone marrow, and the two types are 98-99% identical, but there are some difference with the protein markers and capabilities of adipose vs. marrow cells.

Marrow cells are better for blood-borne diseases like lymphomas, whereas adipose-derived stem cells seems to be much more effective than marrow for structural issues. The concentration of adipose cells per gram of source material is actually 500-1000x greater than bone marrow from same patient. They have the ability to differentiate into a multitude of other cells including chondrocytes. This has incredible potential for how doctors treat sports injuries and aging issues.

Anthony set the stage for the importance of the research,”Most sports or age injuries are due to ligament or cartilage damage to the extent that most of them are bone on bone. So what if we could take Mrs. Smith who’s 55 and played tennis most of her life but can’t play anymore and doesn’t want to have knee replacement surgery. We can take cells out of the fat in her own body, attach them to a scaffold to induce chondrocytes, insert them into the meniscal cartilage area, and as time goes by with normal rehabilitation, her body regrows cartilage in her knees and her pain is gone.”

Anthony is excited about the implications for creating tissue for repairs, wound healing, burns, tendon injury, etc., all coming out of cells taken from adipose tissue. Read the rest of this entry »

About Science Exchange

We are transforming scientific collaboration by creating a marketplace where scientists can order experiments from the world's top labs.

Check the Science Exchange blog for updates, opinions, guest posts and the latest happenings at Science Exchange HQ!

Visit Science Exchange →

Subscribe to the blog
Never miss a post! Science Exchange blog posts delivered right to your inbox.
Thank you for joining the SciEx revolution!
Powered By WPFruits.com